Form 4: Checkpoint Therapeutics Director Sells Shares in Merger, Receives Cash and Contingent Value Rights

Checkpoint Therapeutics Director Lindsay A. Rosenwald MD disposed of 207,007 shares of common stock in connection with a merger agreement, receiving $4.10 per share in cash and one contingent value right per share.

Summary

• Lindsay A. Rosenwald MD, a Director of Checkpoint Therapeutics, Inc. (CKPT), reported changes in his beneficial ownership of the company's common stock.
• On May 28, 2025, Mr. Rosenwald acquired 12,195 shares of common stock at a price of $0.00 per share, which includes restricted shares vesting over time subject to his continued board service.
• On May 29, 2025, he acquired an additional 50,000 shares of common stock at a price of $1.29 per share.
• On May 30, 2025, Mr. Rosenwald disposed of 207,007 shares of common stock in connection with an offer made pursuant to the Agreement and Plan of Merger, dated March 9, 2025, and amended April 14, 2025.
• For each share disposed, he received $4.10 net in cash, plus one contractual contingent value right (CVR).
• Each CVR represents the right to receive a payment ranging from $0.20 to $0.70, contingent on certain milestone payments related to the regulatory approval for cosibelimab in the European Union.
• The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application for cosibelimab receives a positive validation outcome by the European Medicines Agency.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger-related share disposition, providing shareholders with a fixed cash payment and potential upside via CVRs tied to future regulatory milestones, indicating a structured exit for the director's holdings.

Positives

• The disposition of shares is part of a merger agreement, indicating a structured exit for shareholders at a pre-determined cash value.
• Shareholders, including the director, receive a contingent value right (CVR) which offers potential additional payments ranging from $0.20 to $0.70 per share.
• The CVR is tied to the regulatory approval of cosibelimab in the European Union, providing an upside potential if the drug achieves market authorization.

Negatives

• The disposition of shares means the director no longer holds direct common stock in Checkpoint Therapeutics, Inc. following the merger transaction.

Risks

• The payment from the Contingent Value Right (CVR) is not guaranteed and is contingent upon specific milestone payments related to the regulatory approval for cosibelimab in the European Union.
• The CVR milestone must be achieved within thirty-six (36) months after the date of a positive validation outcome by the European Medicines Agency; failure to meet this timeline or obtain approval would result in no CVR payment.

Future Outlook

The future outlook includes the potential for additional payments to shareholders via Contingent Value Rights (CVRs), which are tied to the successful regulatory approval of cosibelimab in the European Union and the achievement of specific milestones within 36 months of EMA positive validation.

Industry Context

This Form 4 filing reflects an insider's transaction related to a merger, which is a common event in the biotechnology and pharmaceutical industries as companies consolidate or assets are acquired. The contingent value right (CVR) mechanism is frequently used in biotech mergers to bridge valuation gaps and provide upside potential tied to future drug development or regulatory milestones, particularly for assets like cosibelimab which are in late-stage regulatory processes.

Related Party Transactions

• The disposition of shares by Director Lindsay A. Rosenwald MD is a transaction with the issuer (Checkpoint Therapeutics, Inc.) as part of a broader merger agreement.

Stakeholder Impact

• Shareholders: Receive $4.10 per share in cash and one CVR per share, providing immediate liquidity and potential future upside based on drug approval.
• Employees: Not directly addressed in this Form 4, but mergers can impact employment.

Next Steps

• Monitoring the progress of cosibelimab's regulatory approval process in the European Union.
• Tracking the achievement of the specific milestones required for CVR payments within the 36-month timeframe after EMA positive validation.

Key Dates

Keywords

Checkpoint Therapeutics, CKPT, Form 4, insider transaction, beneficial ownership, merger agreement, contingent value right, CVR, cosibelimab, European Union, regulatory approval, pharmaceuticals, biotechnology